■ Abstract Objective The aim of this study was to identify clinical, magnetic resonance imaging (MRI) and biological markers predictive of long-term clinical response to interferon beta (IFN beta) therapy in patients with relapsing-remitting multiple sclerosis (RRMS). Methods Sixty-eight patients treated with IFN beta were followed over a 6-year period. Relapse rate and disability progression were evaluated throughout the study.We considered suboptimal clinical response to be either the presence of sustained disability progression, or more than two relapses. Baseline and 12-month demographic, clinical and MRI findings, as well as the development of neutralizing antibodies (NAbs) against IFN beta during the first year of therapy were analyzed as predictors of long-term clinical outcome. Results "Black holes" on MRI were the best baseline predictor of disability progression (odds ratio [OR] 6.8; p < 0.001).At 1 year, both male gender (OR 4.9; p = 0.009) and NAbs (OR 7.3; p = 0.003) were independently associated with a high risk of developing subsequent disability. The presence of gadolinium enhancement, both at baseline (OR 4.7; p = 0.005) and on the 1-year MRI scan (OR 7.9; p = 0.002), was the unique variable associated with the number of relapses over the study period. Conclusions Variables assessable within the first year of treatment significantly influence relapse rate and disability progression in patients with RRMS treated with IFN beta. These findings may help clinicians to make decisions regarding therapy regimen over time, and highlight the need for a prognostic algorithm.
■ Key words interferon beta · predictors · neutralizing antibodies · MRI sentation is predictive of the clinical course of the disease and the extent of disability [8] [9] [10] . Additionally, the presence of enhancing lesions, even on a single MRI scan, indicates an increased risk of clinical relapses and forecasts subclinical demyelination in untreated patients with a CIS or relapsing-remitting (RR) MS [11] [12] [13] . Interferon beta (IFN beta) reduces the overall frequency of MS attacks by approximately 30 % compared with placebo in therapeutic trials [14] [15] [16] . These trials, however, have failed to identify any clinical or MRI factors, other than treatment-arm assignment, predictive of the response to IFN beta treatment. Some clinical parameters, such as age, disease duration, Expanded Disability Status Scale (EDSS) score [17] , relapse rate before IFN beta therapy, and the development of neutralizing antibodies (NAbs) against IFN beta, have been reported as potential predictive factors of therapeutic response [18] [19] [20] [21] [22] . Nevertheless, the results of these studies are conflicting and are related to short-term followup. There are no long-term studies on patients treated with IFN beta for RRMS investigating the role of clinical and MRI features in predicting long-term clinical outcome, and providing a model to help clinicians to make decisions about therapy regimen over time. The purpose of this study was to determine whether clinical, MRI, and biological markers, both at baseline and after 12 months of treatment with IFN beta, are valuable tools for predicting clinical outcome over a long period of treatment in patients with RRMS.
Methods

■ Study design and participants
Details of the study materials and methods have been published elsewhere [23] [24] [25] . Briefly, 68 patients with clinically definite RRMS, a disease duration of less than 10 years, and EDSS scores between 1.0 and 5.0 were recruited to receive IFN beta-1a (Rebif®, Ares Serono, Geneva, Switzerland), 11 or 33 µg three times weekly (tiw), for 2 years. When the study began, this drug had not been licensed, and doses different from those used today were tested. At the end of this period, owing to limited availability of the then unlicensed IFN beta-1a, 16 of the 68 patients were selected to continue therapy with IFN beta-1a, 33 µg tiw, whilst the remainder was switched to IFN beta-1b (Betaferon®, Schering, Berlin, Germany), 8 MIU subcutaneously tiw.
■ Clinical assessment
During the study period, a neurological examination was performed and disability scored on the EDSS every 6 months. Patients who discontinued treatment continued to visit the MS outpatient Centre as often as when they were being treated. The number of clinical exacerbations, EDSS scores, and other medical events that occurred were recorded at each visit.An exacerbation was defined as the appearance or reappearance of one or more symptoms attributable to MS, accompanied by objective deterioration lasting at least 24 hours on neurological examination in the absence of fever and preceded by neurological stability for at least 30 days. In the case of relapse, each patient was treated with a high dose of steroids (methylprednisolone, 1 g daily for 5 consecutive days). The neurologists who conducted the original study continued to examine patients throughout the 6-year observation period.
■ Definitions of response to IFN beta therapy
We considered two definitions of clinical response to IFN beta based on disability progression and the number of relapses."Suboptimal responders" were patients who over the study period developed either an increase ≥ 1.0 point on the EDSS that persisted for at least two consecutive scheduled visits separated by a 6-month interval, or more than two relapses.
■ NAbs assessment
Sera collected before the commencement of treatment and at 3, 6, 9, and 12 months were tested for (NABS). The presence of NAbs to IFN beta against 10 IU of recombinant IFN beta-1a was determined by a cytopathic effect assay, as previously described [25] . Titres were calculated using the Kawade's method and expressed as t 1/10 ; namely, the dilution of serum that reduces 10 laboratory units (LU/mL) of IFN to 1 LU/mL [26] [27] [28] . A positive NAbs sample was defined as a titre of at least 1:20 neutralizing units. The patient was judged to be antibodypositive during the 12-month period according to the definition "once positive, always positive".
■ MRI protocol
Patients underwent MRI scanning monthly from 6 months before treatment to 9 months after the start of treatment. Further MRI scans were performed at month 12 (after the first treatment year), month 18, month 24 (second year) and month 72 (sixth year) [24] . The annual MRI scan was delayed by 30 days in those patients who had been treated with steroids during a relapse in order to avoid any influence of the steroids on the scans. Brain MRI was performed using a superconducting 0.5 T magnet-Toshiba S 50. The MRI protocol included transaxial T1-weighted (T1WI; TR 400, TE 18), proton density (PD), and T2-spin-echo images (TR 2500, TE 30/90). The gadolinium (Gd)-enhanced T1WI scans were obtained in the transaxial plane, between 5 and 10 minutes after injection of 0.1 mmol/kg of gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA).All transaxial scans were collected with a 5 mm slice thickness, 1 mm gap, using a 25 cm field of view and 160 ϫ256 matrix.
■ MRI analysis MRI scans at baseline (i. e. before treatment commencement) and at month 12 (i. e. after 1 year of therapy) were examined. We measured the Gd-enhancing lesion load (Gd-LL); T2 hyperintense lesion load on the PDWI (T2-LL); T1 hypointense lesion load ("black holes") on post-contrast T1WI (T1-hypointense LL). The Gd-LL, T2-LL, and T1-hypointense LL were calculated from the transaxial scans using the "Dispim" display program (DL Plummer, University College London, UK) that incorporates a semi-automated edge-detection and contouring algorithm [29, 30] . For these measurements, the images for both the baseline and the first year were reanalysed by the same observer (E. G.), who was blinded to the order of the scans. A "hypointense lesion" was defined as any region with low signal intensity relative to the surrounding white matter, visible on enhanced T1WI, and corresponding to a region of high signal intensity on T2WI. Gdenhanced MRI scans performed at baseline and after 12 months of treatment were considered "active" by the presence of at least one enhancing lesion.
■ Statistical analysis
Statistical significance between proportions was calculated using Pearson's Chi-square test or, for two frequencies, the z-test. Statistical significance between two groups was calculated using the independent-samples t-test or the Mann-Whitney test.All p-values quoted are two-sided; p-values less than 0.05 were considered significant. Demographic-Clinical-Biological and MRI-related variables at baseline and after 1 year were also analysed separately by multivariate analyses. To identify the predictors of disease progression and relapses, odds ratios, their corresponding 95 % confidence intervals (CIs), and p-values were computed using the logistic regression model (forward stepwise regression). In each subsequent step, the regression equation comprised those predictors reaching specific thresholds of F-and pvalues (for predictor inclusion: F ≥ 1 and p ≤ 0.05; for exclusion: F < 1 and p > 0.05). Baseline clinical-related variables (age, gender, disease duration, EDSS score, number of relapses in the 2 years prior to IFN beta therapy) and MRI-related variables (presence/absence of Gd-enhancement, T2-LL, T1-hypointense LL) potentially predictive of the response to IFN beta therapy were included in the model evaluating the outcomes between the sixth year and baseline. One-year clinicalrelated variables (age, gender, disease duration, EDSS score, number of relapses during the first year of IFN beta therapy) and MRI-related variables (presence/absence of Gd enhancement, T2-LL, T1-hypointense LL) as well as the development of NAbs during the first year of treatment were included in the model evaluating the outcomes between the sixth year and after the first year of IFN beta therapy. All statistical analyses were performed using STATISTICA version 6.0 (Statsoft s. r. l., Italy).
Results
We studied 68 patients (47 females, 21 males) with a mean age of 30.5 years (standard deviation 7.3; range 18-40) and a mean disease duration of 5.0 years (range 1-10). The median EDSS score at entry was 2.0 (range 1.0-5.0). The mean length of follow-up was 70.5 months (median 72, range 1-72). The patients were clinically active, with a mean annualized exacerbation rate over the previous 2 years of 1.6 . Clinical, MRI, and NAbs findings over the 6-year period are shown in detail elsewhere [24, 25] . Out of the 68 patients 11 (16.2 %) discontinued treatment during the 6-year period. Reasons for stopping the therapy were: one patient died following a myocardial infarct, an event which was not related to treatment; breast cancer (one patient), severe cognitive dysfunction (one patient), physician's or participant's perception of therapy ineffectiveness (four patients), and dislike of injection (two patients). Two women who remained under IFN-β treatment for 5 years dropped out only after deciding to become pregnant. The median duration of treatment exposure in the 11 patients who discontinued treatment was 23 months (range 4-64). No significant differences in terms of clinical outcome (i. e. relapse rate and EDSS change) were found between patients who discontinued treatment and patients who were still being treated. All patients who discontinued treatment had a complete follow-up except for one patient who dropped out of the study 40 days after the commencement of IFN beta and was not included in the analysis. Thus, the results from the present study are based on 67 patients. At the end of the 6-year follow-up, the median EDSS score was 2.5 (range 1.0-6.5). When the EDSS scores at the end of follow-up were compared with the baseline examination using a categorical analysis, 38 of 67 (56.7 %) patients had unchanged (± 0.5 points) or improved EDSS scores, and 29 (43.3 %) had worsened scores (by ≥ 1.0 point). Sixteen patients (23.9 %) developed a disability progression during the first 12 months of therapy, 11 patients (16.4 %) between 1 st and 2 nd year and 28 patients from year 2 to year 6. During the study, 34 of 67 (50.7 %) patients had ≤ 2 relapses. Among the 29 patients with disease progression, 19 had > 2 relapses (65.5 %).
Thirty-seven (55.2 %) patients at baseline and 16 (23.9 %) patients at 1 year showed an "active" scan. Median T2-LL was 11.1 cm 3 at baseline and 9.5 cm 3 at 12 months. Median T1-hypointense LL was 1.8 cm 3 at baseline and 1.8 cm 3 at 12 months. NAbs with a titre ≥ 1:20 were detected in 17 (25.4 %) patients within the first year of treatment; five of these patients had a titre ≥ 1:100. As already reported, NAbs titres decreased over time and, by year 6, NAbs were detected in only 7.1 % of patients [25] .
■ Relationship between patient characteristics and clinical outcome
Baseline T1-hypointense LL and T2-LL were significantly higher in patients with disability progression than in those with an EDSS score that was unchanged or improved. No differences in other demographic, clinical, or MRI variables were found (Table 1) . Baseline Gd enhancement was associated with the number of relapses over the subsequent 6 years (β = -0.41 [95 % CI: -0.64, -0.18]; p < 0.001; multiple R 2 of the model was 17 %; p < 0.001). Patients with a baseline "active" scan showed a higher number of relapses over 6 years than patients with inactive scans at baseline (adjusted mean, 3.9 relapses [95 % CI: 3.1, 4.7] versus 1.6 [95 % CI: 0.6, 2.6]; p < 0.001 for post-hoc comparison with Bonferroni's test). At 1 year, male gender, longer disease duration, the presence of NAbs, and higher T2-LL and T1-hypointense LL were associated with disability progression ( Table 2 ). The presence of Gd-enhancement on MRI was associated with the number of relapses between the first and sixth year (β = -0.40 [95 % CI: -0, 63, -0, 17]; p < 0.001; multiple R 2 of the model was 16 %; p < 0.001). Patients with an "active" scan at 1 year had a higher number of relapses over the following 5 years than patients with an inactive scan at baseline (adjusted mean, 3.9 relapses [95 % CI: 2.9, 4.9] versus 1.9 [95 % CI: 1.3, 2.4]; p < 0.001 for post-hoc comparison with Bonferroni's test). There was no different clinical outcome at year 6 between patients treated with 11 or 33 µg IFN beta-1a for 2 years. Similarly, patients who continued treatment with IFN beta-1a over the entire study period had an outcome not different from those who switched to IFN beta-1b after 2 years.
■ Predictors of suboptimal clinical response
According to the two definitions of clinical response to IFN beta based on the number of relapses or disability progression the number of suboptimal responders was equal to 33/67 and 29/67 during the 6-year follow-up, 26/67 and 28/67 during a 5-year time interval. Baseline and 1-year predictors of a suboptimal response to therapy after 6 years by a forward stepwise logistic regression model are reported in Tables 3 and 4. At the baseline analysis, a higher T1-hypointense LL was associated with a higher risk of developing disability progression, whereas at 1-year, male gender and the presence of NAbs were associated with a higher risk of developing disability during the subsequent 5 years (Table 3 ). An "active" scan was predictive of the occurrence of more than 2 relapses over the study period both at baseline and at the 1-year analysis (Table 4) . Note: all values are means (SD), unless indicated otherwise. We defined as worsened a patient with an increase of 1.0 point in EDSS score between the sixth year of follow-up and baseline, persisting for at least two consecutive scheduled visits and separated by a 6-month interval. We considered an MRI active scan as one with at least one enhancing lesion EDSS Expanded Disability Status Scale; MRI magnetic resonance imaging; SD standard deviation; T1-hypointense LL T1-hypointense lesion load on transaxial post-contrast T1-weighted images; T2-LL T2-hyperintense lesion load on transaxial proton density images Note: all values are means (SD), unless indicated otherwise. We defined as worsened a patient with an increase of 1.0 point in EDSS score between the sixth year and the first year of follow-up, persisting for at least two consecutive scheduled visits and separated by a 6-month interval. We considered an MRI active scan as one with at least one enhancing lesion EDSS Expanded Disability Status Scale; MRI magnetic resonance imaging; NAbs neutralizing antibodies; SD standard deviation; T1-hypointense LL T1-hypointense lesion load on post-contrast transaxial T1-weighted images; T2-LL T2-hyperintense lesion load on transaxial proton density images There is, however, a high degree of variability in the response from one patient to another. In this study, we identified, during a 6-year follow-up of MS patients undergoing treatment, some baseline and 1-year characteristics predictive of clinical response to IFN beta therapy. For the purpose of the study, clinical response to IFN beta has been considered according to the frequency of relapses and absence of disability progression during the study period. Having used the criterion of ≥ 1.0-point increase in EDSS score confirmed after 6 months, and a long follow-up (i. e. 6 years), we have probably significantly improved the validity of these results, by excluding those patients who experienced only transient disease progression,as recently suggested [31] . Other definitions of response (i.e the number of patients who reached an EDSS equal to 6.0 at the end of the study) have not been applied because only 7 patients reached an EDSS score of 6.0 at the end of follow-up, too small a number to allow a reliable statistical comparison.
The results from a multivariate analysis indicate that T1-hypointense LL was the unique baseline factor associated with a higher risk of disability progression, whereas male gender and the presence of NAbs became significant predictors 12 months after the commencement of IFN beta therapy. Previous short follow-up studies (i. e. maximum 2-3 years) in patients with RRMS have shown a significant but weak relationship between baseline lesion load and EDSS score [32, 33] . The higher predictive value of lesion burden seen in our study could be related to the relatively longer period of follow-up. Results from the multivariate analysis showed T1-hypointense LL as the unique baseline factor associated with a higher risk of disability progression. T1 "black holes" provide in vivo evidence of axonal loss [34, 35] , and are strongly correlated with clinical disability in MS [36, 37] . There is little evidence that T1-hypointense lesions predict progression of disability, although there is growing consensus suggesting that disability measures should be expected to correlate more strongly with T1-hypointense lesions than with T2-hyperintense lesions [33] . In the present study, analysis 12 months after the commencement of IFN beta therapy reveals that T1 "black holes" are no longer a significant predictor of disease progression, while male gender emerges as an important predictive factor. This finding implies that among patients with a higher baseline T1-hypointense LL (i. e. those patients who are at greater risk of disability progression) there is a subgroup of females in which IFN beta substantially modifies the natural history of the disease, reducing the probability of progression. In support of this hypothesis, the female/male ratio in patients without disease progression is 2.5 at baseline, but 3.9 at 1 year. There is some clinical and MRI evidence for a gender difference in the response to IFN beta therapy in patients with MS suggesting a significant benefit on disability progression in women but not in men [38, 39] . Although the mechanisms for treatment-by-gender interaction in patients with MS are poorly understood, changes in tissue hormone responsiveness induced by IFN beta treatment might play a role in explaining the different response to therapy and the ability of gender to predict the clinical outcome found at 1 year, but not at baseline [40, 41] . Furthermore, it has been clearly demonstrated that Note: MRI categories were defined according to median split of T1-hypointense LL distribution. The development of disability progression has been defined as a worsening in EDSS score of 1.0 point, persisting for at least two consecutive scheduled visits and separated by a 6-month interval CI confidence interval; T1-hypointense LL T1-hypointense lesion load on transaxial post-contrast T1-weighted images; NAbs neutralizing antibodies against IFN beta CI confidence interval; MRI activity the presence of at least one Gd-enhancing lesion on transaxial post-contrast T1-weighted images male sex increases the likelihood of having "black holes" [42, 43] . This association must be taken into account in the interpretation of the results. NAbs to IFN beta were observed in 25 % of our patients, and their development in the first year of treatment predicted disability progression over a 5-year period. The development of NAbs in patients with RRMS has been reported to be associated with reduced clinical efficacy, i. e. relapse activity [21, 22, [44] [45] [46] and EDSS progression [22, 44, 45] . The ability of NAbs to predict disability progression but not the occurrence of relapses in the present study may suggest that the former becomes evident only in studies of longer duration, and the latter is transient and better seen in short-term trials.
The presence of Gd-enhancement both at baseline and at 1 year was the unique variable associated with the number of relapses over the study period. Previous studies have demonstrated that the high sensitivity of Gd-enhanced MRI allows the detection of subclinical disease activity, and the method seems to be helpful in identifying patients at high risk of developing relapses [12, 47] . Here, we can confirm that the presence of Gd activity after 12 months of therapy can identify response to IFN beta in the individual patient [48] and should allow more rational clinical decision making.
In summary, despite some study limitations (i. e. the small number of patients,the absence of a control group, and the switch of a proportion of patients from IFN beta-1a to IFN beta-1b), we suggest that factors at the beginning and during IFN beta therapy -including gender, MRI disease burden, MRI activity, and NAbs status -can be predictive of long-term clinical outcome. However, as previously reported in natural history studies, markers of disease activity differ from those of disability progression and this is not surprising, considering the complexity of the MS disease process. These findings emphasize the need to establish a prognostic algorithm that takes into account multiple factors (e. g. demographic, clinical and subclinical) and will assist physicians in the prediction of the patient's response to therapy.
